Cordant Inc’s Pacific Biosciences PACB Stock Holding History

Cordant Inc’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-163	Closed	-$193	–	91
2025 Q1	$193	Buy	+163	New	+$250	﹤0.01%	106

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cordant Inc's PACB Position: Q2 2025 in Review

Cordant Inc sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 163 shares — an estimated $193 sold.

Cordant Inc first reported a position in PACB in Q1 2025 and held it in 1 quarter. The position peaked at $193 in Q1 2025. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

Cordant Inc reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
Cordant Inc sold 163 Pacific Biosciences shares in Q2 2025, an estimated $193.
Cordant Inc first reported a position in Pacific Biosciences in Q1 2025 and held it in 1 quarter.
Cordant Inc's Pacific Biosciences position peaked at $193 in Q1 2025.
207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Cordant Inc's 13F filing for Q2 2025, filed 15 Jul 2025.